Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.50 |
| ▸ | BTK | Q06187 | 2/20 | 0.47 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.45 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.43 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL858239 | 1.00 | LRRK2 (0.50) | LRRK2BTKPIM2CYP1A1CYP1A2 | |
| SCHEMBL858237 | 0.84 | LRRK2 (0.56) | LRRK2BTKMEN1GAAMAPT | |
| SCHEMBL1362011 | 0.84 | PIM2 (0.46) | LRRK2PIM2CYP1B1MAOBDYRK3 | |
| SCHEMBL1362007 | 0.84 | PIM2 (0.46) | LRRK2PIM2CYP1B1MAOBDYRK3 | |
| SCHEMBL1363467 | 0.83 | LRRK2 (0.55) | LRRK2BTKMEN1GAAMAPT | |
| SCHEMBL859098 | 0.83 | LRRK2 (0.54) | LRRK2BTKCYP1A1CYP1A2CYP1B1 | |
| SCHEMBL1362095 | 0.83 | PIM2 (0.47) | LRRK2BTKPIM2MEN1KMT2A | |
| SCHEMBL856856 | 0.83 | PIM2 (0.47) | LRRK2BTKPIM2MEN1KMT2A | |
| SCHEMBL857267 | 0.81 | AAK1 (0.57) | PIM2BCHEDYRK3ROCK2PRKD3 | |
| SCHEMBL1363682 | 0.81 | AAK1 (0.57) | PIM2BCHEDYRK3ROCK2PRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067434-B2 | Compounds and methods for development of Ret modulators | PLEXXIKON INC. (US) | 2011-11-29 | — | — | US | claimed |
| US-20100324065-A1 | Compounds and methods for development of Ret Modulators | PLEXXIKON INC | 2010-12-23 | — | — | US | claimed |
| US-7504509-B2 | Compounds and methods for development of Ret modulators | PLEXXIKON, INC. (US) | 2009-03-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324065-A1 | Compounds and methods for development of Ret Modulators | RET, GFRA3, GFRA1 | LRRK2 96/4885BTK 1809/4885PIM2 2832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.